Table 1.

Baseline patients characteristics (n = 46a)

N (%)
Age (median and range)66 (33–84)
Gender
 Male29 (63)
 Female17 (37)
Primary tumor resected31 (67.4)
Site of primary
 Left colon15 (32.6)
 Rectal20 (43.5)
 Right colon11 (23.9)
Histology
 Adenocarcinoma (mucinous)11 (23.9)
 Adenocarcinoma (nonmucinous)35 (76.1)
Differentiation
 Poor7 (15.2)
 Moderate38 (82.6)
 Well1 (2.2)
Dukes staging at diagnosis
 B5 (10.9)
 C15 (32.6)
 D26 (56.5)
Extent of metastatic disease
 Liver31 (67.4)
 Lung20 (43.5)
 Omentum/peritoneum14 (30.4)
 Distant lymph nodes11 (23.9)
 Other11 (23.9)
 Soft tissue3 (6.5)
Radiotherapy to primary11 (23.9)
Lines of prior therapy
 13 (6.5)
 222 (47.8)
 316 (34.8)
 43 (6.5)
 61 (2.2)
 91 (2.2)
  • aOverall 47 patients were screened for the study; one patient (1015) was excluded based on the presence of an NRAS mutation before commencing cetuximab and did not undergo any trial-related procedures. One patient (1031) had rapid deterioration prior to cetuximab and did not start treatment.